Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Phase

Condition

Hepatic Fibrosis

Liver Disorders

Primary Biliary Cholangitis

Treatment

N/A

Clinical Study ID

NCT02823366

KY20151230-5

Ages 18-70
All Genders

Study Summary

Ursodeoxycholic acid (UDCA) has been the only treatment for PBC approved by US and European drug administrations. Long-term use of UDCA(13-15 mg/kg/day) in patients with PBC improves serum liver biochemistries and survival free of liver transplantation However, about 40% of patients do not respond to UDCA optimally as assessed by known criteria for biochemical response. Those patients represent the group in need for additional therapies, having increased risk of disease progression and decreased survival free of liver transplantation. Both lab research and some clinical studies suggest that fenofibrate could improve cholestasis in multiple ways including reduce of bile acid synthesis, increase of biliary secretion and anti-inflammation effect. Here we start a random, open and parallel clinical research to explore the effect of fenofibrate in the PBC treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Signed informed consent
Patient with PBC defined by 2 in 3 of the following criteria: a.Positiveantimitochondrial antibody type M2; b.Abnormal serum alkaline phosphatases (ALP > 1,5N) and aminotransferase (AST or ALT > 1N) activities; c.Histological hepaticinjuries consistent with PBC.
Had been treated with UDCA more than 6 months, and failed to achieve a completebiochemical response.

Exclusion

Exclusion Criteria:

Pregnancy or desire of pregnancy.
Breast-feeding.
Co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liverdisease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fattyliver disease, Wilson's disease and hemochromatosis.
History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy,or poorly controlled ascites).
History of urolithiasis, nephritis or renal failure (clearance of creatinine < 60ml/mn).
Hepatotoxic drugs use before recruiting.
Fenofibrate anaphylaxis.

Study Design

January 01, 2016

December 31, 2023

Connect with a study center

Xijing Hosipital
Xi'an, Shaanxi 710032
China
Active - Recruiting
Xijing Hosipital
Xi`an, Shaanxi 710032
China
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.